How Immunotherapy Works

Every cell in your body carries surface proteins that act like identification cards, telling your immune system whether they're friend or foe. Cancer cells often display abnormal proteins—mutated versions of normal proteins or proteins that shouldn't appear in adult tissues—that mark them as dangerous. However, cancer cells are master disguises: they evolved from your own cells, so they carry many normal ID badges that trick your immune system into ignoring them.

Immunotherapy drugs called checkpoint inhibitors work by blocking the fake "don't attack me" signals that cancer cells broadcast. Other approaches use engineered antibodies that bind specifically to abnormal proteins found only on cancer cells, painting a bright target for immune cells to recognize. In CAR-T cell therapy, doctors remove a patient's T cells and genetically reprogram them to recognize a specific protein on cancer cells—essentially giving immune cells a new pair of glasses to see threats they previously missed.

This recognition step is crucial because your immune system encounters billions of cells daily and must distinguish genuinely dangerous cells from healthy ones. By helping immune cells identify the molecular signatures unique to diseased cells, immunotherapy transforms your body's surveillance system from colorblind to eagle-eyed, able to spot threats hiding in plain sight among healthy tissue.

Your immune system contains powerful T cells capable of destroying cancer, but they often sit idle because of built-in safety mechanisms designed to prevent autoimmune disease. These safety mechanisms work through "checkpoint" proteins—molecular brakes that T cells must engage before attacking any cell, ensuring they don't accidentally destroy healthy tissue. Cancer cells exploit these checkpoints by expressing proteins that press the brake pedal, effectively paralyzing nearby immune cells.

Checkpoint inhibitor drugs like pembrolizumab and nivolumab block these brake proteins, particularly one called PD-1 on T cells and its partner PD-L1 on cancer cells. When the drug prevents these proteins from connecting, it's like cutting the brake lines: suddenly T cells that were parked and idle roar into action. The T cells don't need to be taught what to attack—they already recognized the cancer as dangerous but were being held back by these inhibitory signals.

Other immunotherapies activate the immune system through different switches. Cytokine therapies use signaling molecules like interleukin-2 to sound a general alarm, recruiting immune cells to the battlefield. Cancer vaccines introduce tumor antigens alongside immune-stimulating adjuvants, deliberately provoking an immune response. These approaches don't just remove obstacles; they actively press the accelerator on immune activation, transforming a sluggish response into an aggressive assault.

Once immunotherapy identifies and activates the right immune cells, the next challenge is numbers. A single T cell that recognizes cancer is useful, but a million copies of that same T cell create an overwhelming force. Your immune system naturally clones successful defenders through a process called clonal expansion—when a T cell finds its target, it divides repeatedly, creating identical copies that share the same target recognition. Immunotherapy supercharges this multiplication process.

In CAR-T cell therapy, this multiplication happens in the laboratory before the cells ever return to the patient. Doctors extract T cells, genetically modify them to recognize cancer, then culture them in bioreactors where they multiply from thousands into hundreds of millions over several weeks. When this expanded army infuses back into the patient's bloodstream, it's like deploying a Special Forces unit that's been cloned into an entire division, all trained for the same mission.

Inside the body, checkpoint inhibitors and cytokine therapies also promote multiplication by creating conditions where activated T cells divide more readily. Cytokines act as growth factors that tell immune cells "make more of yourselves," while removing checkpoint brakes eliminates signals that would otherwise limit cell division. The result is an exponential expansion: one activated T cell becomes two, then four, then eight, scaling up until cancer cells face overwhelming numerical superiority from attackers specifically trained to recognize them.

When a T cell recognizes its target cancer cell, it doesn't simply mark it for removal—it becomes a direct assassin. The T cell binds tightly to the cancer cell's surface and releases toxic proteins called perforins and granzymes through the narrow gap between them. Perforins punch holes in the cancer cell's membrane, like a molecular drill, while granzymes pour through these holes and activate self-destruction programs inside the cancer cell, causing it to fragment in a controlled process called apoptosis.

Other immune cells join the destruction through different mechanisms. Natural killer cells also deploy perforins and granzymes but don't require the same specific recognition signals as T cells, making them a rapid-response force. Antibody-based immunotherapies coat cancer cells in targeting proteins that attract macrophages—large immune cells that engulf and digest tagged enemies whole, then display pieces of them to further activate the adaptive immune response.

The destruction isn't instantaneous. A single T cell can kill a cancer cell, detach, and move on to kill again—one study showed individual T cells could destroy multiple targets in succession. As immunotherapy expands the population of these serial killers and removes the inhibitions preventing their attack, tumors that had grown unchecked begin to shrink. Imaging scans sometimes show tumors getting temporarily larger before shrinking, as immune cells flood in and inflammation peaks before the cancer cells finally die and clear away.

The most remarkable feature of immunotherapy is what happens after the cancer is destroyed. Unlike chemotherapy, which stops working the moment you stop taking it, immunotherapy can create lasting immunity through specialized memory T cells. These cells develop during the initial immune response and persist in your body for years or even decades, continuously circulating through blood and lymph nodes like veteran soldiers who never forget an enemy's face.

Memory T cells exist in a state of readiness. They don't actively attack anything most of the time, but they maintain the molecular recognition machinery for cancer-specific proteins, and they can multiply and activate far more rapidly than naive immune cells encountering a threat for the first time. If cancer tries to return months or years after successful immunotherapy, these memory cells detect it immediately and launch a swift, massive response—often destroying the recurrence before it becomes detectable by scans.

This immunological memory explains why some patients experience durable remissions lasting years after immunotherapy ends, something rarely seen with conventional treatments. In melanoma, for instance, some patients treated with checkpoint inhibitors remain cancer-free a decade later without ongoing treatment. Their immune systems learned to recognize melanoma and maintain that knowledge. This represents a fundamental shift from managing cancer as a chronic disease requiring continuous treatment to potentially curing it through a time-limited intervention that establishes permanent surveillance.